Table 1.

Baseline characteristics of participants in the HARPdoc RCT by intervention arm.

Demographic measure	HARPdoc	BGAT
N	49	50
n (%) in USA	8 (16.3)	9 (18.0)
Age (years)—mean ± sd	56.7 ± 12.2	51.9 ± 14.1
Female gender—n (%)	29 (59.2)	26 (52.0)
Ethnicity—n (%)
White	46 (93.9)	49 (98.0)
African/Caribbean	0 (0.0)	1 (2.0)
Hispanic	1 (2.0)	0 (0.0)
Mixed	1 (2.0)	0 (0.0)
Other	1 (2.0)	0 (0.0)
Body Mass Index (BMI)—mean ± sd	[N = 48] 27.0 ± 5.5	[N = 50] 25.8 ± 4.4
Duration of type 1 diabetes (years)—mean ± sd	38.1 ± 16.0	33.6 ± 14.7
Glycated haemoglobin, HbA1c, %—mean ± sd	[N = 48] 7.4 ± 1.1	[N = 50] 7.4 ± 1.3
Glycated haemoglobin, HbA1c, mmol/mol—mean ± sd	[N = 48] 57.1 ± 12.2	[N = 50] 57.4 ± 14.1
Duration of experience of SH—n (%)
<2 years	2 (4.1)	2 (4.0)
≥2 years to <5 years	14 (28.6)	8 (16.0)
≥5 years to <10 years	10 (20.4)	9 (18.0)
≥10 years	23 (46.9)	31 (62.0)
Baseline rate of SH—Median [IQR]	5.0 [2.0–11.0]	5.0 [2.0–12.0]
Diabetes complications and co-morbidities
Pancreas transplant—n (%)	2 (4.1)	0 (0.0)
Islet transplant—n (%)	0 (0.0)	0 (0.0)
Renal transplant—n (%)	1 (2.0)	0 (0.0)
Symptomatic (peripheral) Neuropathy—n (%)	11 (22.4)	10 (20.0)
Retinopathy—n (%)	[N = 48] 34 (70.8)	[N = 50] 37 (74.0)
Number of comorbidities—mean ± sd	[N = 49] 7.2 ± 5.3	[N = 46]7.2 ± 5.0

n = number; N = number of participants with data.